Navigation Links
Actavis Receives Approval of Levetiracetam Oral Solution in the U.S.
Date:1/21/2009

MORRISTOWN, N.J., Jan. 21 /PRNewswire/ -- Actavis Group, the international generic pharmaceuticals company, today announced that it has received approval from the U.S. Food & Drug Administration to market Levetiracetam Oral Solution. Distribution of the product has commenced.

Levetiracetam Oral Solution is available in the 100mg/mL strength and is the generic equivalent of Keppra(R) Oral Solution by UCB, Incorporated. Levetiracetam Oral Solution is used in the treatment of partial onset seizures in adults and children with epilepsy. Annual U.S. sales of Keppra(R) Oral Solution were US$95.9 million for the 12 months ending September 2008 according to IMS Health data.

Commenting on the new approval, Doug Boothe, CEO of Actavis in the United States said:

"The approval of Levetiracetam Oral Solution demonstrates our continuing commitment to introduce new generic products to the marketplace, as well as highlights our expertise in developing and manufacturing a wide range of dosage forms. Actavis' drive to be a leader in generic pharmaceuticals is supported by one of the largest product development pipelines in the industry. "

About Actavis

Actavis is one of the world's leading generic pharmaceutical companies specializing in the development, manufacture and sale of generic pharmaceuticals. With headquarters in Iceland, Actavis has operations in 40 countries, with 11,000 employees. The United States is the company's single largest market. Actavis' U.S. operations are located in New Jersey, Maryland, North Carolina and Florida.

More information about Actavis in the United States can be found at www.actavis.us.

Information in this press release may contain forward-looking statements with respect to the financial condition, results of operations and businesses of Actavis. By their nature, forward-looking statements and forecasts involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from that expressed or implied by these forward-looking statements. These factors include, among other things, exchange rate fluctuations, the risk that research and development will not yield new products that achieve commercial success, the impact of competition, price controls and price reductions, the risk of loss or expiration of patents or trade marks, difficulties of obtaining and maintaining governmental approvals for products, the risk of substantial product liability claims, exposure to environmental liability.


'/>"/>
SOURCE Actavis Group
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Actavis Receives Approval of Generic Wellbutrin XL(R) 150mg in the U.S.
2. Actavis Receives Approval of Generic Wellbutrin XL(R) 300mg in the U.S.
3. Harvard Business School Publishes a Case Study on Robert Wessman and Actavis
4. Actavis Extends Portfolio With Four New Products in the U.S.
5. Actavis Confirms its Patent Challenge of Kings Avinza(R)
6. Actavis Launches Amlodipine Tablets in the U.S.
7. Actavis Launches Carvedilol Tablets in the U.S.
8. Horphag Research Receives 2008 Frost & Sullivan North American Health Ingredients Excellence In Research Award
9. Samplify Systems Receives Top Honors From Electronic Products and EDN Magazines
10. Medicsight PLC Receives Additional Information Request for FDA 510(k) Clearance
11. Abbott Receives FDA CLIA Waiver for Use of Five Additional Cartridges on the i-STAT Handheld Blood Analyzer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... United Benefit Advisors ... the latest addition to its growing list of Partner Firms. S.S. Nesbitt ... from Orlando to Huntsville and in between. , Harnessing the experience and insights ...
(Date:2/10/2016)... , ... February 10, 2016 , ... ... time Emmy award winner and inspirational speaker Jan Fox will serve as keynote ... Speaking Boldly will provide participants with tools to more effectively communicate with their ...
(Date:2/10/2016)... Beach, Florida (PRWEB) , ... February 10, 2016 ... ... Country Club) announced that it has been awarded the prestigious Distinguished Emerald Club ... World award program conducted by BoardRoom magazine, one of the most respected trade ...
(Date:2/10/2016)... CA (PRWEB) , ... February 10, 2016 , ... Workrite ... and most versatile series of monitor mounts ever. , “Our goal was to ... and easy to install system that we have ever created.” said Darren Hulsey, Product ...
(Date:2/10/2016)... ... February 09, 2016 , ... A new leadership team for ... FHU President Joe Wiley made the announcement Monday night, Feb. 8, prior to the ... graduate of FHU and the creator of GO! Camp, has been named director. Gayle ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... England och PITTSBURGH ... Erbjudandet lämnas inte, och detta pressmeddelande ... indirekt, i eller till, och inga anmälningssedlar ... av aktieägare i, något land där Erbjudandet, ... accept av Erbjudandet skulle strida mot tillämpliga ...
(Date:2/10/2016)... February 10, 2016 A new report from business intelligence ... states that the Alzheimer,s disease market will more than double from just under ... Compound Annual Growth Rate (CAGR) of 11%. Canada , ... , Spain , the UK, and Japan ... forecast period. --> Canada , France ...
(Date:2/10/2016)... , Feb. 10, 2016 Urologix, the ... the treatment of Benign Prostatic Hyperplasia (BPH), announces new ... Ash Keswani , a medical device industry veteran of ... the Limited Liability Company.  Plymouth, ... service lines, Cooled ThermoTherapy™ and Prostiva® RF Therapy, will ...
Breaking Medicine Technology: